Senzime expands into the French market driven by new clinical Guidelines

Report this content

Press release: Uppsala, October 29, 2020. Senzime AB (publ) today announces that the company has entered into an exclusive agreement with The Surgical Company (formerly Sebac) for the French market, and the first order to a university hospital in France is ready to be delivered.  Market entry is driven by the new clinical guidelines in France supporting the use of Senzime’s products in surgery.


“France is one of the world's most important medical technology markets and thus an extremely important market in our commercial plan. The Surgical Company is a leader in the French Anesthesia market, and we are proud that they have chosen to include our products in their portfolio,” says Pia Renaudin, Senzime’s CEO.

The Surgical Company (Sebac) was founded in 1974 and has for almost 50 years launched revolutionary product in the field of anesthesia where they have gained great know-how and a wide network of contacts. TSC has over 3,500 customers in France and focus on innovative products with great patient needs in the Anesthesia area. Senzime already has orders that are ready to be delivered, as the interest from French anesthesiologists has been great after the company’s participation in the national anesthesia meeting in Paris last year.

In 2020, the French Anesthesia Association has updated its guidelines for monitoring neuromuscular blockade. The reason for the update, according to the authors, is the extensive research that shows a high frequency of residual neuromuscular blockade with a risk of critical complications and increased mortality as a result, while it is seen that the use of an objective monitor helps to counteract this. The recommendation states that an objective monitor should be used in connection with all administration of muscle relaxants.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB            

Phone: +46 70-813 34 17, e-post:


About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399,,  is Certified Adviser for Senzime.  

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 28, 2020, 08:45 CET.



Documents & Links